Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.
- Author:
Guo-Wen LIN
1
;
Gao-Xiang LI
1
;
Bo DAI
1
;
Ding-Wei YE
1
;
Yun-Yi KONG
2
;
Yue WANG
1
;
Yi-Jun SHEN
1
Author Information
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords: abiraterone acetate; castration-resistant prostate cancer; clinical activity; docetaxel-naïve; docetaxel-pretreated
- MeSH: Aged; Aged, 80 and over; Androstenes/therapeutic use*; Antineoplastic Agents, Hormonal/therapeutic use*; China; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Humans; Male; Middle Aged; Prednisone/therapeutic use*; Prostatic Neoplasms, Castration-Resistant/mortality*; Retrospective Studies; Survival Rate; Treatment Outcome
- From: Asian Journal of Andrology 2019;21(2):131-136
- CountryChina
- Language:English
- Abstract: This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 146 patients with docetaxel-naïve group (103 cases) and docetaxel-resistant group (43 cases) were enrolled from the Shanghai Cancer Center (Shanghai, China) in this retrospective cohort study. The efficacy endpoints were prostate-specific antigen response rate, prostate-specific antigen progression-free survival, clinical/radiographic progression-free survival, and overall survival in response to abiraterone plus prednisone. Significantly higher prostate-specific antigen response rate was found in docetaxel-naïve group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naïve group compared to docetaxel-resistant group, respectively. The univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall survival. To sum up, our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naïve and docetaxel-resistant Chinese patients. Moreover, higher PSA response rate and longer overall survival were observed in the docetaxel-naïve group, which suggested that abiraterone was more effective for docetaxel- naïve patients than for docetaxel failures.
